AUCTORES
Globalize your Research
Case Report | DOI: https://doi.org/10.31579/2578-8949/062
Department of Cardiology, Servergazi State Hospital, Denizli, Turkey
*Corresponding Author: K. Issoual, Departement of Dermatology, CHU Hassan II FEZ Morocco.
Citation: K. Issoual, a. Alaoui, k. Achehboune, s. Gallouj et al (2020). Photo-onycholysis : A particular chemotherapy-induced complication 5(1); Doi:10.31579/2578-8949/062
Copyright: © This is an open-access article distributed under the terms of The Creative Commons. Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 17 January 2020 | Accepted: 18 February 2020 | Published: 24 February 2020
Keywords: subungual hematoma ; photosensitization; Cyclophosphamise
Onycholysis or photo-onycholysis is a partial or total separation of the nail from the nail-bed secondary to chemotherapy, either alone or associated to ultraviolet phototherapy. It’is not a common side effect of anticancer therapy, even rarer with Paclitaxel. We report here one case.
A 59-year-old woman patient, with invasive ductal carcinoma on the left breast with bone metastases, diagnosed in 2014, and treated by several chemotherapy protocols : 3 cycles of FEC, it’s a combination of 5 fluorouracil, Epirubicin and cyclophosphamide ; stopped in 2014. After that, and from 2014 to 1016, she received 6 cycles of docetaxel, Then she was under capecitabine for 4 months before treating her by a Pacli weekly protocol (Paclitaxel) since 08/2016 till this day.
At our consultation, the patient had a diffusé pigmentation of all the nails of both hands and feet since 2015, followed by inflammation and then detachment of the nails and intense pain, with the result of nauseating yellowish liquid from the unguéal table 4 months ago (10 weeks after the administration of Paclitaxel). On clinical examination, diffuse pigmentation of the nails of the hands and feet, with total onycholysis interesting only the fingernails of the hands, the pressure being very painful welding a thick yellowish liquid nauseating from the ungueal tablet. Our diagnosis was that of phototoxic onycholysis, and concidering the different delays we before related this effect to Paclitaxel.
Photo-onycholysis is a particular case of phototoxicity. It’s a rare side effect, mostly encountered in patients treated with taxanes particularly Docetaxel (30-40%) and rarely described with the use of Paclitaxel. Nail modifications, such as pigmentation or onycholysis were found in only 2% of patients treated with Paclitaxel.
Nail damage during this treatment is summarized as onycholysis with subungual hematoma by photosensitization. The nail tablet acts as a magnifying glass concentrating ultraviolet rays on the nail bed. This results in very painful nail detachment and finally subungual aseptic abscesses. This complication generally develops between 10 and 12 weeks from the start of treatment [3]. In our case, the photo-onycholysis associated with Paclitaxel was chosen because of the delay. The toenails did not show onycholysis, only hyperpigmentation, which is in favor of phototoxicity. As for hyperpigmentation, it is classic during chemotherapy treatment, in our case, several agents used in the therapeutic protocol may be involved in our patient: Epidebicin, Cyclophosphamise, 5FU, Docétaxel as well as Paclitaxel, these last 4 molecules are responsible for photosensitization[1].
Several preventive measures can be implemented to diminish this effect; propose Opaque Nail Polish, rich in silicon during and up to 3-6 months after the end of chemotherapy, peri-ungual hydration, the wearing of refrigerated gloves during the administration of chemotherapy as well as baths with Chlorhexidine or simply diluted bleach. Treatment is symptomatic with antiseptic baths and antibiotic therapy to treat superinfections, in the most severe cases discontinuation or change of molecule should be discussed as appropriate [4].
Progressively, onycholysis disappears completely within a few months after the end of chemotherapy; hyperpigmentation usually subsides, at least partially, after the cytotoxic treatment is stopped. In rare cases, the lesions are permanent. [1]
Onycholysis is an unusual reaction that may occur in some patients receiving weekly low-dose Paclitaxel therapy. This reaction affects the quality of life of patients but does not justify discontinuation of therapy. However, clinicians should be aware of the possibility of this effect and should be prepared to counsel patients on various preventive measures and sun protection.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
